

Medicine Shortage Communication

August 22, 2025

Zypadhera (Olanzapine pamoate monohydrate <210 mg / 300 mg / 405 mg> powder and solvent for prolonged release suspension for injection): supply shortage

Dear Healthcare Professional,

CHEPLAPHARM Registration GmbH, is notifying healthcare professionals about an ongoing critical shortage of Zypadhera.

Overview of situation

- **Since 2024, there is a shortage of Zypadhera. The shortage concerns all strengths of the medicine < 210 mg / 300 mg / 405 mg > and is expected to last until October 2025.**
- **The shortage was initially due to manufacturing problems with the 50 mm needle supplied with the medicine.**
- **The shortage has worsened due to additional manufacturing and supply chain problems at the existing site and while implementing a new manufacturing site and a quality defect which led to particles in two batches of the medicine. The affected batches were not released on the market which put further constraints on the supply situation.**
- **The shortage affects all EU/ EEA countries where the product is marketed (Austria, Belgium, Bulgaria, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Greece, Hungary, Ireland, Italy, The Netherlands, Norway, Romania, Slovenia, Slovakia and Sweden).**

Mitigation measures

To reduce the impact of the shortage, the MAH is engaging with the European Medicines Agency and relevant National Competent Authorities on appropriate mitigation measures. The following actions have been taken to address and improve the situation:

- increased manufacturing shifts at the manufacturing site;
- implementation of corrective and preventative actions to address the quality defect;
- reallocation of stock within the EU and from global supply, in a fair and equitable manner.

During the shortage, healthcare professionals should:

- **Not prescribe Zypadhera to new patients to reserve / guarantee supply for patients who are already taking this medicine and who do not have suitable alternatives.**
-

- **If switching existing patients from Zypadhera to another antipsychotic, take the following into consideration:**
 - **There is no other olanzapine depot formulation available in the EU.**
 - **Follow relevant guidance issued at national level when switching medicines.**
 - **There are no systematically collected data to specifically address switching patients from Zypadhera to other antipsychotic medicinal products.**
 - **Olanzapine pamoate salt results in a slow continuous release of olanzapine that is complete approximately six to eight months after the last injection. Therefore, clinician supervision, especially during the first 2 months after discontinuation of Zypadhera, is needed when switching to another antipsychotic product and is considered medically appropriate.**
 - **Healthcare professionals should be aware that switching patients to another antipsychotic may carry a risk of relapse. Patients should therefore be monitored for signs and symptoms of a relapse; alternative formulations such as oral treatments may be associated with lower compliance.**

Background on the shortage

Zypadhera is indicated for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine. It has been authorised in the EU since November 2008 and is available as a 210 mg, 300 mg and 405 mg powder and solvent for prolonged release suspension for injection.

The critical shortage of Zypadhera started in 2024, following a manufacturing problem with the 50 mm needles supplied with the medicine. The shortage has now worsened due to other manufacturing problems, such as:

- Unavailability of active substance vials and delivery challenges
- Change in the needle manufacturing site and the manufacturer's name.
- Malfunction of manufacturing equipment and the need to purchase new equipment.
- A quality defect as visible particles have been identified in 2 batches of Zypadhera. These batches were not released to the market.
- A third-party manufacturer had to change excipient manufacturer which caused further delays in production.

As a result of the quality defect, production was paused, which further worsened the shortage situation. That issue has been resolved and production resumed. However, due to the manufacturing and supply issues outlined, the shortage is expected to last until October 2025 in all EU/EEA countries where the medicine is marketed.

For additional information on the shortage, consult <your country's shortage register *(if available)*> <or your [national competent authority](#).>

Company contact point

<Contact point details for access to further information, including relevant website address(es), telephone numbers and a postal address>

Annexes (if applicable)

<Link/reference to other available relevant information, such as information on the website of a competent authority>